Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium

Britton Trabert; Roberta B Ness; Wei-Hsuan Lo-Ciganic; Megan A Murphy; Ellen L Goode; Elizabeth M Poole; Louise A Brinton; Penelope M Webb; Christina M Nagle; Susan J Jordan; Harvey A Risch; Mary Anne Rossing; Jennifer A Doherty; Marc T Goodman; Galina Lurie; Susanne K Kjær; Estrid Hogdall; Allan Jensen; Daniel W Cramer; Kathryn L Terry; Allison Vitonis; Elisa V Bandera; Sara Olson; Melony G King; Urmila Chandran; Hoda Anton-Culver; Argyrios Ziogas; Usha Menon; Simon A Gayther; Susan J Ramus; Aleksandra Gentry-Maharaj; Anna H Wu; Celeste Leigh Pearce; Malcolm C Pike; Andrew Berchuck; Joellen M Schildkraut; Nicolas Wentzensen; Australian Ovarian Cancer Study Group, Australian Cancer Study (Ovarian Cancer)

doi:10.1093/jnci/djt431

Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium

Britton Trabert, Roberta B Ness, Wei-Hsuan Lo-Ciganic, Megan A Murphy, Ellen L Goode, Elizabeth M Poole, Louise A Brinton, Penelope M Webb, Christina M Nagle, Susan J Jordan, Harvey A Risch, Mary Anne Rossing, Jennifer A Doherty, Marc T Goodman, Galina Lurie, Susanne K Kjær, Estrid Hogdall, Allan Jensen, Daniel W Cramer, Kathryn L TerryAllison Vitonis, Elisa V Bandera, Sara Olson, Melony G King, Urmila Chandran, Hoda Anton-Culver, Argyrios Ziogas, Usha Menon, Simon A Gayther, Susan J Ramus, Aleksandra Gentry-Maharaj, Anna H Wu, Celeste Leigh Pearce, Malcolm C Pike, Andrew Berchuck, Joellen M Schildkraut, Nicolas Wentzensen, Australian Ovarian Cancer Study Group, Australian Cancer Study (Ovarian Cancer)

Department of Pathology

218 Citations (Scopus)

Abstract

BACKGROUND: Regular aspirin use is associated with reduced risk of several malignancies. Epidemiologic studies analyzing aspirin, nonaspirin nonsteroidal anti-inflammatory drug (NSAID), and acetaminophen use and ovarian cancer risk have been inconclusive.

METHODS: We analyzed pooled data from 12 population-based case-control studies of ovarian cancer, including 7776 case patients and 11843 control subjects accrued between 1992 and 2007. Odds ratios (ORs) for associations of medication use with invasive epithelial ovarian cancer were estimated in individual studies using logistic regression and combined using random effects meta-analysis. Associations between frequency, dose, and duration of analgesic use and risk of ovarian cancer were also assessed. All statistical tests were two-sided.

RESULTS: Aspirin use was associated with a reduced risk of ovarian cancer (OR = 0.91; 95% confidence interval [CI] = 0.84 to 0.99). Results were similar but not statistically significant for nonaspirin NSAIDs, and there was no association with acetaminophen. In seven studies with frequency data, the reduced risk was strongest among daily aspirin users (OR = 0.80; 95% CI = 0.67 to 0.96). In three studies with dose information, the reduced risk was strongest among users of low dose (<100 mg) aspirin (OR = 0.66; 95% CI = 0.53 to 0.83), whereas for nonaspirin NSAIDs, the reduced risk was strongest for high dose (≥500 mg) usage (OR = 0.76; 95% CI = 0.64 to 0.91).

CONCLUSIONS: Aspirin use was associated with a reduced risk of ovarian cancer, especially among daily users of low-dose aspirin. These findings suggest that the same aspirin regimen proven to protect against cardiovascular events and several cancers could reduce the risk of ovarian cancer 20% to 34% depending on frequency and dose of use.

Original language	English
Journal	National Cancer Institute. Journal (Print)
Volume	106
Issue number	2
Pages (from-to)	djt431
ISSN	0027-8874
DOIs	https://doi.org/10.1093/jnci/djt431
Publication status	Published - Feb 2014

Keywords

Acetaminophen
Anti-Inflammatory Agents, Non-Steroidal
Anticarcinogenic Agents
Aspirin
Australia
Case-Control Studies
Data Collection
Denmark
Drug Administration Schedule
Female
Great Britain
Humans
Incidence
Logistic Models
Neoplasms, Glandular and Epithelial
Odds Ratio
Ovarian Neoplasms
Protective Agents
Risk
United States

Access to Document

10.1093/jnci/djt431

Cite this

Trabert, B., Ness, R. B., Lo-Ciganic, W.-H., Murphy, M. A., Goode, E. L., Poole, E. M., Brinton, L. A., Webb, P. M., Nagle, C. M., Jordan, S. J., Risch, H. A., Rossing, M. A., Doherty, J. A., Goodman, M. T., Lurie, G., Kjær, S. K., Hogdall, E., Jensen, A., Cramer, D. W., ... Australian Ovarian Cancer Study Group, Australian Cancer Study (Ovarian Cancer) (2014). Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. National Cancer Institute. Journal (Print), 106(2), djt431. https://doi.org/10.1093/jnci/djt431

Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. / Trabert, Britton; Ness, Roberta B; Lo-Ciganic, Wei-Hsuan et al.
In: National Cancer Institute. Journal (Print), Vol. 106, No. 2, 02.2014, p. djt431.

Research output: Contribution to journal › Journal article › Research › peer-review

Trabert, B, Ness, RB, Lo-Ciganic, W-H, Murphy, MA, Goode, EL, Poole, EM, Brinton, LA, Webb, PM, Nagle, CM, Jordan, SJ, Risch, HA, Rossing, MA, Doherty, JA, Goodman, MT, Lurie, G, Kjær, SK , Hogdall, E, Jensen, A, Cramer, DW, Terry, KL, Vitonis, A, Bandera, EV, Olson, S, King, MG, Chandran, U, Anton-Culver, H, Ziogas, A, Menon, U, Gayther, SA, Ramus, SJ, Gentry-Maharaj, A, Wu, AH, Pearce, CL, Pike, MC, Berchuck, A, Schildkraut, JM, Wentzensen, N & Australian Ovarian Cancer Study Group, Australian Cancer Study (Ovarian Cancer) 2014, 'Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium', National Cancer Institute. Journal (Print), vol. 106, no. 2, pp. djt431. https://doi.org/10.1093/jnci/djt431

@article{b226dbb3c64c4345af7c5e096072d578,

title = "Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium",

abstract = "BACKGROUND: Regular aspirin use is associated with reduced risk of several malignancies. Epidemiologic studies analyzing aspirin, nonaspirin nonsteroidal anti-inflammatory drug (NSAID), and acetaminophen use and ovarian cancer risk have been inconclusive.METHODS: We analyzed pooled data from 12 population-based case-control studies of ovarian cancer, including 7776 case patients and 11843 control subjects accrued between 1992 and 2007. Odds ratios (ORs) for associations of medication use with invasive epithelial ovarian cancer were estimated in individual studies using logistic regression and combined using random effects meta-analysis. Associations between frequency, dose, and duration of analgesic use and risk of ovarian cancer were also assessed. All statistical tests were two-sided.RESULTS: Aspirin use was associated with a reduced risk of ovarian cancer (OR = 0.91; 95\% confidence interval [CI] = 0.84 to 0.99). Results were similar but not statistically significant for nonaspirin NSAIDs, and there was no association with acetaminophen. In seven studies with frequency data, the reduced risk was strongest among daily aspirin users (OR = 0.80; 95\% CI = 0.67 to 0.96). In three studies with dose information, the reduced risk was strongest among users of low dose (<100 mg) aspirin (OR = 0.66; 95\% CI = 0.53 to 0.83), whereas for nonaspirin NSAIDs, the reduced risk was strongest for high dose (≥500 mg) usage (OR = 0.76; 95\% CI = 0.64 to 0.91).CONCLUSIONS: Aspirin use was associated with a reduced risk of ovarian cancer, especially among daily users of low-dose aspirin. These findings suggest that the same aspirin regimen proven to protect against cardiovascular events and several cancers could reduce the risk of ovarian cancer 20\% to 34\% depending on frequency and dose of use.",

keywords = "Acetaminophen, Anti-Inflammatory Agents, Non-Steroidal, Anticarcinogenic Agents, Aspirin, Australia, Case-Control Studies, Data Collection, Denmark, Drug Administration Schedule, Female, Great Britain, Humans, Incidence, Logistic Models, Neoplasms, Glandular and Epithelial, Odds Ratio, Ovarian Neoplasms, Protective Agents, Risk, United States",

author = "Britton Trabert and Ness, \{Roberta B\} and Wei-Hsuan Lo-Ciganic and Murphy, \{Megan A\} and Goode, \{Ellen L\} and Poole, \{Elizabeth M\} and Brinton, \{Louise A\} and Webb, \{Penelope M\} and Nagle, \{Christina M\} and Jordan, \{Susan J\} and Risch, \{Harvey A\} and Rossing, \{Mary Anne\} and Doherty, \{Jennifer A\} and Goodman, \{Marc T\} and Galina Lurie and Kj{\ae}r, \{Susanne K\} and Estrid Hogdall and Allan Jensen and Cramer, \{Daniel W\} and Terry, \{Kathryn L\} and Allison Vitonis and Bandera, \{Elisa V\} and Sara Olson and King, \{Melony G\} and Urmila Chandran and Hoda Anton-Culver and Argyrios Ziogas and Usha Menon and Gayther, \{Simon A\} and Ramus, \{Susan J\} and Aleksandra Gentry-Maharaj and Wu, \{Anna H\} and Pearce, \{Celeste Leigh\} and Pike, \{Malcolm C\} and Andrew Berchuck and Schildkraut, \{Joellen M\} and Nicolas Wentzensen and \{Australian Ovarian Cancer Study Group, Australian Cancer Study (Ovarian Cancer)\}",

year = "2014",

month = feb,

doi = "10.1093/jnci/djt431",

language = "English",

volume = "106",

pages = "djt431",

journal = "National Cancer Institute. Journal (Print)",

issn = "0027-8874",

publisher = "Oxford University Press",

number = "2",

}

TY - JOUR

T1 - Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer

T2 - a pooled analysis in the Ovarian Cancer Association Consortium

AU - Trabert, Britton

AU - Ness, Roberta B

AU - Lo-Ciganic, Wei-Hsuan

AU - Murphy, Megan A

AU - Goode, Ellen L

AU - Poole, Elizabeth M

AU - Brinton, Louise A

AU - Webb, Penelope M

AU - Nagle, Christina M

AU - Jordan, Susan J

AU - Risch, Harvey A

AU - Rossing, Mary Anne

AU - Doherty, Jennifer A

AU - Goodman, Marc T

AU - Lurie, Galina

AU - Kjær, Susanne K

AU - Hogdall, Estrid

AU - Jensen, Allan

AU - Cramer, Daniel W

AU - Terry, Kathryn L

AU - Vitonis, Allison

AU - Bandera, Elisa V

AU - Olson, Sara

AU - King, Melony G

AU - Chandran, Urmila

AU - Anton-Culver, Hoda

AU - Ziogas, Argyrios

AU - Menon, Usha

AU - Gayther, Simon A

AU - Ramus, Susan J

AU - Gentry-Maharaj, Aleksandra

AU - Wu, Anna H

AU - Pearce, Celeste Leigh

AU - Pike, Malcolm C

AU - Berchuck, Andrew

AU - Schildkraut, Joellen M

AU - Wentzensen, Nicolas

AU - Australian Ovarian Cancer Study Group, Australian Cancer Study (Ovarian Cancer)

PY - 2014/2

Y1 - 2014/2

N2 - BACKGROUND: Regular aspirin use is associated with reduced risk of several malignancies. Epidemiologic studies analyzing aspirin, nonaspirin nonsteroidal anti-inflammatory drug (NSAID), and acetaminophen use and ovarian cancer risk have been inconclusive.METHODS: We analyzed pooled data from 12 population-based case-control studies of ovarian cancer, including 7776 case patients and 11843 control subjects accrued between 1992 and 2007. Odds ratios (ORs) for associations of medication use with invasive epithelial ovarian cancer were estimated in individual studies using logistic regression and combined using random effects meta-analysis. Associations between frequency, dose, and duration of analgesic use and risk of ovarian cancer were also assessed. All statistical tests were two-sided.RESULTS: Aspirin use was associated with a reduced risk of ovarian cancer (OR = 0.91; 95% confidence interval [CI] = 0.84 to 0.99). Results were similar but not statistically significant for nonaspirin NSAIDs, and there was no association with acetaminophen. In seven studies with frequency data, the reduced risk was strongest among daily aspirin users (OR = 0.80; 95% CI = 0.67 to 0.96). In three studies with dose information, the reduced risk was strongest among users of low dose (<100 mg) aspirin (OR = 0.66; 95% CI = 0.53 to 0.83), whereas for nonaspirin NSAIDs, the reduced risk was strongest for high dose (≥500 mg) usage (OR = 0.76; 95% CI = 0.64 to 0.91).CONCLUSIONS: Aspirin use was associated with a reduced risk of ovarian cancer, especially among daily users of low-dose aspirin. These findings suggest that the same aspirin regimen proven to protect against cardiovascular events and several cancers could reduce the risk of ovarian cancer 20% to 34% depending on frequency and dose of use.

AB - BACKGROUND: Regular aspirin use is associated with reduced risk of several malignancies. Epidemiologic studies analyzing aspirin, nonaspirin nonsteroidal anti-inflammatory drug (NSAID), and acetaminophen use and ovarian cancer risk have been inconclusive.METHODS: We analyzed pooled data from 12 population-based case-control studies of ovarian cancer, including 7776 case patients and 11843 control subjects accrued between 1992 and 2007. Odds ratios (ORs) for associations of medication use with invasive epithelial ovarian cancer were estimated in individual studies using logistic regression and combined using random effects meta-analysis. Associations between frequency, dose, and duration of analgesic use and risk of ovarian cancer were also assessed. All statistical tests were two-sided.RESULTS: Aspirin use was associated with a reduced risk of ovarian cancer (OR = 0.91; 95% confidence interval [CI] = 0.84 to 0.99). Results were similar but not statistically significant for nonaspirin NSAIDs, and there was no association with acetaminophen. In seven studies with frequency data, the reduced risk was strongest among daily aspirin users (OR = 0.80; 95% CI = 0.67 to 0.96). In three studies with dose information, the reduced risk was strongest among users of low dose (<100 mg) aspirin (OR = 0.66; 95% CI = 0.53 to 0.83), whereas for nonaspirin NSAIDs, the reduced risk was strongest for high dose (≥500 mg) usage (OR = 0.76; 95% CI = 0.64 to 0.91).CONCLUSIONS: Aspirin use was associated with a reduced risk of ovarian cancer, especially among daily users of low-dose aspirin. These findings suggest that the same aspirin regimen proven to protect against cardiovascular events and several cancers could reduce the risk of ovarian cancer 20% to 34% depending on frequency and dose of use.

KW - Acetaminophen

KW - Anti-Inflammatory Agents, Non-Steroidal

KW - Anticarcinogenic Agents

KW - Aspirin

KW - Australia

KW - Case-Control Studies

KW - Data Collection

KW - Denmark

KW - Drug Administration Schedule

KW - Female

KW - Great Britain

KW - Humans

KW - Incidence

KW - Logistic Models

KW - Neoplasms, Glandular and Epithelial

KW - Odds Ratio

KW - Ovarian Neoplasms

KW - Protective Agents

KW - Risk

KW - United States

UR - https://www.scopus.com/pages/publications/84893873955

U2 - 10.1093/jnci/djt431

DO - 10.1093/jnci/djt431

M3 - Journal article

C2 - 24503200

SN - 0027-8874

VL - 106

SP - djt431

JO - National Cancer Institute. Journal (Print)

JF - National Cancer Institute. Journal (Print)

IS - 2

ER -

Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this